A detailed history of Pathstone Holdings, LLC transactions in Genmab A/S stock. As of the latest transaction made, Pathstone Holdings, LLC holds 15,000 shares of GMAB stock, worth $315,300. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,000
Previous 10,060 49.11%
Holding current value
$315,300
Previous $252,000 44.84%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$23.84 - $28.48 $117,769 - $140,691
4,940 Added 49.11%
15,000 $365,000
Q2 2024

Aug 14, 2024

SELL
$25.13 - $30.27 $4,146 - $4,994
-165 Reduced 1.61%
10,060 $252,000
Q1 2024

May 13, 2024

SELL
$26.43 - $32.77 $13,215 - $16,385
-500 Reduced 4.66%
10,225 $305,000
Q4 2023

Feb 14, 2024

BUY
$27.94 - $35.44 $299,656 - $380,094
10,725 New
10,725 $341,000

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.8B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Pathstone Holdings, LLC Portfolio

Follow Pathstone Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pathstone Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pathstone Holdings, LLC with notifications on news.